Value of PET restaging after chemotherapy for non-Hodgkin's lymphoma: Implications for consolidation radiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 66, Issue 4, 2006, Pages 961-965

  Kahn, Shannon T ^a   Flowers, Christopher ^a   Lechowicz, Mary Jo ^a   Hollenbach, Kathryn ^b   Johnstone, Peter A S ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BetaStatistics   (United States)

Author keywords

Consolidation radiotherapy; Non Hodgkins lymphoma; Positron emission tomography

Indexed keywords

CHEMOTHERAPY; DATABASE SYSTEMS; HISTOLOGY; MEDICAL COMPUTING; ONCOLOGY; RADIOTHERAPY;

CONSOLIDATION RADIATION THERAPY (CRT); NEGATIVE COHORTS; NON-HODGKIN'S LYMPHOMA (NHL);

POSITRON EMISSION TOMOGRAPHY;

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CONFIDENCE INTERVAL; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RECURRENT DISEASE; RELAPSE; RR INTERVAL; TIME SERIES ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOTHERAPY, ADJUVANT; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 33750378735     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.07.1365     Document Type: Article

References (22)

1. Kumar R., Bhargava P., Bzkurt M.F., et al. Positron emission tomography imaging in evaluation of cancer patients. Indian J Cancer 40 (2003) 87-100
2. Kumar R., Mallard I., Schuster S.J., et al. Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas. Radiol Clin N Am 42 (2004) 1083-1100
3. Nyman R.S., Rehn S.M., Glimelius B.L., et al. Residual mediastinal masses in Hodgkin's disease: Prediction of size with MR imaging. Radiology 170 (1989) 435-440
4. North L.B., Fuller L.M., Sullivan-Halley J.A., et al. Regression of mediastinal Hodgkin's disease after therapy: Evaluation of time interval. Radiology 164 (1987) 599-602
5. Delcambre C., Reman O., Henry-Amar M., et al. Clinical relevance of gallium-67 scintigraphy in lymphoma before and after therapy. Eur J Nucl Med 27 (2000) 176-184
6. Gasparini M., Bombardierei E., Castellani M., et al. Gallium-67 scintigraphy evaluation of therapy in non-Hodgkin's lymphoma. J Nucl Med 39 (1998) 1586-1590
7. Front D., Bar-Shalom R., Mor M., et al. Aggressive non-Hodgkin's lymphoma: Early prediction of outcome with 67 Ga scintigraphy. Radiology 214 (2002) 253-257
8. Kostakoglu L., and Goldsmith S.J. Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: Is it time to shift gears?. Eur J Nucl Med 27 (2000) 1564-1578
9. Mikhaeel N.G., Timothy A.R., Odoherty M.J., Hain S., and Maisey M.N. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma, comparison with CT. Leuk Lymphoma 39 (2000) 543-553
10. Spaegen K., Stroobants S., Dupont P., et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (18F FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: Is FDG-PET a valid alternative to conventional diagnostic methods?. J Clin Oncol 19 (2001) 414-419
11. Zinzani P.L., Magagnoli M., Chierichetti F., et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol 10 (1999) 1181-1184
12. Jerusalem G., Beguin Y., Fassotte M.F., et al. Whole body emission tomography using F-18-fluorodeoxyglusoce for post treatment evaluation in Hodgkin's diseases and non-Hodgkin's lymphoma has a higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94 (1999) 429-433
13. Foo S.S., Mitchell S.U., Berlangieri C.L., et al. Positron emission tomography scanning in the assessment of patients with lymphoma. Int Med J 34 (2004) 388-397
14. Coiffier B. How to interpret the radiological abnormalities that persist after treatment in non-Hodgkin's lymphoma patients?. Ann Oncol 10 (1999) 1141-1143
15. Mikhaeel N.G., Timothy A.R., Hain S.F., et al. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol 11 (2000) 147-150
16. Zijlstra J.M., Lindauer-van der, Werf G., Hoekstra O.S., Hooft L., Riphagen I.I., and Huijgens P.C. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: A systematic review. Haematologica 91 (2006) 522-529
17. Hutchings M., Eigtved A.I., and Specht L. FDG-PET in the clinical management of Hodgkin lymphoma. Crit Rev Onc/Hematol 52 (2004) 19-32
18. Miller T.P., Dahlberg S., Cassady J.R., et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Eng J Med 339 (1998) 21-26
19. Horning S.J., Weller E., Kyungmann K., et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 22 (2004) 3032-3038
20. Kiffer J.D., Berlangieri S.U., Scott A.M., et al. The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer. Lung Cancer 19 (1998) 167-177
21. Ciernek I.F., Dizendorf E., Baumert B.G., et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): A feasibility study. Int J Radiat Oncol Biol Phys 57 (2003) 853-863
22. Nestle U., Hellwig D., Schmidt S., et al. 2-Deoxy-2-(18F) fluoro-D-glucose positron emission tomography in target volume definition for radiotherapy of patients with non-small-cell lung cancer. Mol Imaging Biol 4 (2002) 257-263